The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) have developed a consensus algorithm for the management of hyperglycemia in type 2 diabetes. The statement, published in the August issue of Diabetes Care, was created for several reasons.
The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) have developed a consensus algorithm for the management of hyperglycemia in type 2 diabetes. The statement, published in the August issue of Diabetes Care, was created for several reasons.
This consensus algorithm is intended to help patients reach recommended glycemic goals; the most recent goal recommended by the ADA is "in general" a hemoglobin A1c (HbA1c) level of <7% or as near <6% as possible without significant hypoglycemia. The consensus opinion, the authors stated, is that an HbA1c level of ≥7% should prompt action to begin or to modify therapy in an attempt to achieve an HbA1c level as close to the nondiabetic range as possible.
Nonetheless, the authors took into account that in most patients with type 2 diabetes, lifestyle recommendations do not result in reaching or maintaining metabolic goals because patients fail to lose weight, regain weight, have progressive disease, or experience a combination of these factors. Therefore, the authors stated that metformin therapy also should be initiated at diagnosis and should be titrated to its maximally effective dose, as tolerated, over a 1- to 2-month period.
If these first steps fail, physicians should add a second medication 2 to 3 months after the initiation of therapy or whenever the HbA1c goal is not reached. However, the only strong consensus regarding this second medication is that physicians should choose insulin, a sulfonylurea, or a thiazolidinedione. In making this decision, physicians must weigh the relative increased costs of the newer agents against the agents' relative benefits.
If these strategies do not result in goal glycemia levels, physicians have other options. When HbA1c is close to the goal (<8.0%), a third oral agent could be added; however, this approach is more costly and potentially less effective in lowering glycemia levels relative to another option: initiating or intensifying insulin therapy. To intensify insulin therapy, injections of short- or rapid-acting insulin before certain meals may be added to the regimen.
The authors stated that their recommended guidelines-achievement and maintenance of nondiabetic glycemic levels through lifestyle changes and metformin treatment, rapid initiation of other medications when glycemic goals are not being reached, and early addition of insulin therapy-may help to substantially reduce the morbidity associated with long-term complications of type 2 diabetes.
SOURCE Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care. 2006;29:1963–1972.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
CVS Caremark Makes Changes in Diabetes Coverage for 2025
Published: November 25th 2024 | Updated: November 25th 2024CVS Caremark has removed several diabetes drugs favor of newer products and generics, and is even favoring an insulin infusion system developed by a company that was cofounded by Alan Lotvin, a former executive at CVS Health.
Read More
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More